Relationship between significant bacteriuria and bladder cancer.

Lorenzo Gómez M1, Cubillo Jimenez J1, Szczesniewski Dudzik J2, Gómez Aristizábal A1, Urrea Serna C1, Arqued Sanagustin J1, Sánchez Sánchez P3, Márquez Sánchez M4, Márquez Sánchez G4, Llanes González3, Padilla Fernández B5

Research Type

Clinical

Abstract Category

Female Lower Urinary Tract Symptoms (LUTS) / Voiding Dysfunction

Abstract 375
Open Discussion ePosters
Scientific Open Discussion Session 5
Wednesday 27th September 2023
12:50 - 12:55 (ePoster Station 3)
Exhibit Hall
Female Infection, Urinary Tract Prospective Study
1. Urology Service of the University Hospital of Salamanca, 2. Urology Area of the Department of Surgery of the University of Salamanca, 3. Urology Department of the Getafe University Hospital, 4. Research Group multidisciplinary Hospital of Salamanca, 5. Urology Department of Surgery of the University of La Laguna
Presenter
Links

Poster

Abstract

Hypothesis / aims of study
Introduction: In women, transitional cell bladder cancer is the most frequent urological tumor, on the other hand, the risk of suffering urinary tract infection (UTI) throughout his life is greater than 50%, being the 2nd cause of community-acquired infection. Significant bacteriuria could influence the transitional cell bladder cancer prognosis (1).
Objective: Establish the relationship between significant bacteriuria and the transitional cell bladder cancer prognosis.
Study design, materials and methods
Materials and method: Prospective study of 138 women older than 18 years, treated for transitional cell bladder cancer by resection, transurethral bladder, plus adjuvant endovesical treatment from 10/04/2012 to 02/13/2022. Significant bacteriuria was a count of >105 CFU/ml of bacteria in the urine culture. Groups: GI (infection group, n=72): patients with significant bacteriuria, GNI (group without infection, n=66): patients who do NOT present significant bacteriuria.

Variables: Age, specific cancer survival, urine culture results, germ in the urine culture, tumor stage T, Symptoms, Bladder cancer stage, adjuvant treatment of bladder cancer, clinical course and recurrence, concomitant diseases, concomitant treatments, toxic habits (smoking), surgical history, allergies. 
Statistics descriptive and multivariate logistic regression analysis. The analysis will be performed using the automatic statistical calculator IBM SPSS Statistics for Windows, Version 25.0. Statistical significance was accepted for p<0.05.
Results
Results: Mean age 69.47 years, SD 11.43, without differences (p=0.4260). Specific mortality due to cancer of 2.90%. A mayor in the presence of significant bacteriuria, there was a 3 times higher probability of recurrence after transitional cell bladder cancer treatment (p=0.014). To greater symptomatic bacteriuria, there was 9.6 times more probability of having worse evolution after bladder cancer treatment (p=0.0002). Correlation in recurrences, the greater the presence of symptomatic bacteriuria (connection coefficient 0.161, p=0.059). With positive urine culture, there was 3.13 times more probability of recurrence (p=0.014). There was a negative trend between the presence of symptomatic bacteriuria and a lower survival (coefficient -0.165, p=0.053).
Interpretation of results
Significant bacteriuria is related to the prognosis of transitional cell bladder cancer: the higher the significant bacteriuria worse clinical increased the histopathological grade in recurrences and more chance of tumor progression. Specific mortality due to cancer increased in the presence of significant bacteriuria
Concluding message
Significant findings bacteriuria is related to the prognosis of transitional cell bladder cancer: the higher the significant bacteriuria worse clinical course, that is, more likely to increase the histopathological grade in recurrences and more chance of tumor progression. In addition, urine cytology positive for malignant cells is more likely find in subsequent consultation checks.
Disclosures
Funding Renal Urological Multidisciplinary Research Group (GRUMUR) Clinical Trial No Subjects Human Ethics Committee CEIm del Área de Salud de Salamanca Helsinki Yes Informed Consent No
22/05/2025 21:17:33